Loading...
•
Mar 31, 2024
Aytu BioScience Q3 2024 Earnings Report
Aytu BioPharma reported third quarter fiscal year 2024 results with increased ADHD portfolio revenue and improved adjusted EBITDA.
Key Takeaways
Aytu BioPharma reported Q3 2024 consolidated net revenue of $18.0 million. The ADHD Portfolio net revenue increased by 49% to $12.3 million. The company's net loss was $2.9 million, or $0.52 per share, and consolidated adjusted EBITDA was positive $0.4 million.
Consolidated net revenue was $18.0 million.
ADHD Portfolio net revenue increased 49% to $12.3 million.
Consumer Health Segment net revenue was $4.0 million, a decrease of 56%.
Net loss was $2.9 million, or $0.52 per share.
Aytu BioScience
Aytu BioScience
Forward Guidance
Aytu BioPharma is focused on its Rx Segment and expects additional expense and margin improvements once manufacturing of ADHD brands is fully transitioned. The company anticipates addressing payor changes within its Pediatric Portfolio and is excited about the overall trajectory of the business as it finishes fiscal 2024.
Positive Outlook
- Focus on Rx Segment to drive long-term stockholder value.
- Expects additional expense and margin improvements from manufacturing transition.
- Strong sales force execution.
- Leveraging innovative Aytu RxConnect platform.
- Continued effective expense management.
Challenges Ahead
- Winding down Consumer Health Segment.
- Negative impact of payor changes within Pediatric Portfolio.
- Discontinued pipeline clinical development programs.
- Softness of pediatric product sales.
- Cyberattack that impacted the entire healthcare industry.